Genprex (NASDAQ:GNPX) Stock Price Down 4.3% – Time to Sell?

Genprex (NASDAQ:GNPX) fell 4.3% on Friday . The stock traded as low as $1.75 and last traded at $1.78. 221,362 shares traded hands during trading, a decline of 70% from the average session volume of 747,446 shares. The stock had previously closed at $1.86.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Genprex in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Genprex Stock Down 4.3%

The stock has a market capitalization of $5.55 million, a PE ratio of -0.07 and a beta of -0.78. The stock’s 50-day moving average is $2.23 and its 200 day moving average is $6.38.

Hedge Funds Weigh In On Genprex

An institutional investor recently raised its position in Genprex stock. Susquehanna International Group LLP boosted its holdings in shares of Genprex (NASDAQ:GNPX) by 11.7% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 340,056 shares of the company’s stock after acquiring an additional 35,661 shares during the quarter. Susquehanna International Group LLP owned approximately 27.20% of Genprex worth $58,000 at the end of the most recent reporting period. 14.05% of the stock is currently owned by institutional investors.

Genprex Company Profile

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.